{
    "clinical_study": {
        "@rank": "142987", 
        "acronym": "Ortataxel", 
        "arm_group": [
            {
                "arm_group_label": "Ortataxel", 
                "arm_group_type": "Experimental", 
                "description": "75 on day 1 every 21 days mg/m2 milligram(s)/square meter (intravenous use)"
            }, 
            {
                "arm_group_label": "Fotemustine", 
                "arm_group_type": "Other", 
                "description": "Fotemustine will act as a calibration arm.\nIntravenous use: 80 mg/m2 on days 1, 15, 30, 45 (induction phase). After a 30 days interval, every 30 days mg/m2 milligram(s)/square meter (maintenance phase)"
            }
        ], 
        "brief_summary": {
            "textblock": "Italian Study On The Efficacy Of Ortataxel In Recurrent Glioblastoma"
        }, 
        "brief_title": "An Efficacy Study Of Ortataxel And Fotemustine In Recurrent Glioblastoma", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Glioblastoma", 
        "condition_browse": {
            "mesh_term": "Glioblastoma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically confirmed GBM. XML File Identifier: 5eAlUsBvalzS0g2DCxqYmADXDBA= Page\n             14/26\n\n          -  GBM in recurrence/progression after surgery, standard radiotherapy and chemotherapy\n             with Temozolomide.\n\n          -  Imaging confirmation of first tumor progression or regrowth as defined by the RANO\n             criteria.\n\n          -  No more than one prior line of chemotherapy (Temozolomide).\n\n          -  Recovery from the toxic effects of prior therapy.\n\n          -  Patients who have undergone recent surgery for recurrent or progressive tumor are\n             eligible provided that:\n\n               1. Surgery must have confirmed the recurrence.\n\n               2. A minimum of 14 days must have elapsed from the day of surgery to randomization.\n                  For core or needle biopsy, a minimum of 7 days must have elapsed prior to\n                  randomization.\n\n               3. Craniotomy or intracranial biopsy site must be adequately healed and free of\n                  drainage or cellulitis, and the underlying cranioplasty must appear intact at\n                  the time of randomization.\n\n          -  Age \u2265 18 years.\n\n          -  Willingness and ability to provide written informed consent and to comply with the\n             study protocol as judged by the investigator.\n\n          -  Karnofsky-PS \u2265 60%.\n\n          -  Stable or decreasing dose of corticosteroids within 5 days prior to randomization.\n\n        Exclusion Criteria:\n\n          -  Patients unable to undergo brain MRI scans with gadolinium (iv).\n\n          -  Pre-existing peripheral neuropathy, grade \u2265 2.\n\n          -  History of intracranial abscess within 6 months prior to randomization.\n\n          -  Anticipation of need for major surgical procedure during the course of the trial.\n\n          -  Treatment with enzyme inducing antiepileptic agents was not allowed. However,\n             patients whose anticonvulsant was changed to a nonenzymeinducing antiepileptic drug\n             were eligible for entry after a 1-week ''washout'' period"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01989884", 
            "org_study_id": "IRFMN-GBM-6272"
        }, 
        "intervention": [
            {
                "arm_group_label": "Ortataxel", 
                "description": "75 mg/m2, IV (in the vein) every 21 days. Number of Cycles: until progression or unacceptable toxicity develops.", 
                "intervention_name": "Ortataxel", 
                "intervention_type": "Drug", 
                "other_name": "IDN5109"
            }, 
            {
                "arm_group_label": "Fotemustine", 
                "description": "Fotemustine will act as a calibration arm. Intravenous use: 80 mg/m2 on days 1, 15, 30, 45 (induction phase). After a 30 days interval, every 30 days mg/m2 milligram(s)/square meter (maintenance phase). Number of cycles: until progression or unacceptable toxicity develops", 
                "intervention_name": "Fotemustine", 
                "intervention_type": "Drug", 
                "other_name": "Muphoran (ATC code: L01AD05)"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Fotemustine"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "December 6, 2013", 
        "location": [
            {
                "contact": {
                    "email": "antonio.silvani@istituto-besta.it", 
                    "last_name": "Antonio Silvani, Me.D.", 
                    "phone": "0223942443", 
                    "phone_ext": "0039"
                }, 
                "facility": {
                    "address": {
                        "city": "Milan", 
                        "country": "Italy", 
                        "zip": "20133"
                    }, 
                    "name": "Carlo Besta Neurological Foundation"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "man.caroli@tin.it", 
                    "last_name": "Manuela Caroli, MD"
                }, 
                "contact_backup": {
                    "last_name": "Andrea Di Cristofori, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Milano", 
                        "country": "Italy"
                    }, 
                    "name": "Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico"
                }, 
                "investigator": {
                    "last_name": "Manuela Caroli, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "gdaprada@fsm.it", 
                    "last_name": "Gian Antonio Da Prada, MD"
                }, 
                "contact_backup": {
                    "email": "mariagrazia.guida@fsm.it", 
                    "last_name": "Maria Grazia Guida"
                }, 
                "facility": {
                    "address": {
                        "city": "Pavia", 
                        "country": "Italy"
                    }, 
                    "name": "Fondazione \"Salvatore Maugeri\""
                }, 
                "investigator": {
                    "last_name": "Gian Antonio Da Prada, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "pace@ifo.it", 
                    "last_name": "Andrea Pace, MD"
                }, 
                "contact_backup": {
                    "email": "veronicavillani@hotmail.it", 
                    "last_name": "Veronica Villani, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Rome", 
                        "country": "Italy"
                    }, 
                    "name": "Istituti Fisioterapici Ospitalieri"
                }, 
                "investigator": [
                    {
                        "last_name": "Andrea Pace, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Veronica Villani, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "2", 
        "official_title": "Multicenter, Randomized, Non Comparative, Open-Label Phase Ii Trial On The Efficacy Of Ortataxel And Fotemustine In Recurrent Glioblastoma", 
        "overall_contact": {
            "email": "irene.floriani@marionegri.it", 
            "last_name": "Irene Floriani, Phd", 
            "phone": "0239014695", 
            "phone_ext": "0039"
        }, 
        "overall_contact_backup": {
            "email": "elena.biagioli@marionegri.it", 
            "last_name": "Elena Biagioli, Chem.Phar.D", 
            "phone": "0239014650", 
            "phone_ext": "0039"
        }, 
        "overall_official": {
            "affiliation": "Fondazione IRCCS Istituto Neurologico \"Carlo Besta\" di Milano", 
            "last_name": "Antonio Silvani, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Italy: Italian Medicines Agency (AIFA)", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "defined as the  percentage  of  patients who are alive and progression free at 6 months after the randomization", 
            "measure": "progression free survival-6", 
            "safety_issue": "No", 
            "time_frame": "after 6 months after randomization"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01989884"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "defined for each patient as the time from the date of randomization to the date of first progression, second primary malignancy or death from any cause, whichever comes first. Subjects not progressed or died at the time of the analysis will be censored at the last disease assessment date", 
                "measure": "progression free survival", 
                "safety_issue": "No", 
                "time_frame": "after 9 months of follow-up for each patient"
            }, 
            {
                "description": "defined as the percentage of patients who are alive at 9 months after the randomization.", 
                "measure": "Overall survival-9", 
                "safety_issue": "No", 
                "time_frame": "9 months after randomization"
            }, 
            {
                "description": "defined as the percentage of patients who are judged by the Investigators to have an objective response as determined by the RANO criteria", 
                "measure": "Objective response rate", 
                "safety_issue": "No", 
                "time_frame": "after 9 months of follow-up for each patient"
            }, 
            {
                "description": "Incidence, nature, severity and seriousness of AEs, according of National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.0\nMaximum toxicity grade experienced by each patient for each specific toxicity\nPercentage of patients experiencing grade 3-4 toxicity for each specific toxicity\nPatients with at least a SAE\nPatients with at least a serious adverse drug reaction (SADR)\nPatients with at least a suspect unexpected serious adverse reaction (SUSAR).", 
                "measure": "Number of patients with AEs, SAEs, SADRs, SUSARs", 
                "safety_issue": "Yes", 
                "time_frame": "after 9 months of follow-up for each patient"
            }, 
            {
                "measure": "treatment compliance", 
                "safety_issue": "No", 
                "time_frame": "9 months after randomization"
            }
        ], 
        "source": "Mario Negri Institute for Pharmacological Research", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mario Negri Institute for Pharmacological Research", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}